Dr. Mitsuo Matsuoka M.D.

Recommended Articles

• How Lung Transplants for Cystic Fibrosis Patients Have Changed

  For those with cystic fibrosis (CF), lung infections are the greatest contributor to death. Lung inflammation, destruction, and chronic infection occurs due to the thick sticky mucus associated with CF.This over-proliferation of mucus occurs due to the mutated gene CFTR which is responsible for the...

• 6 Reasons Why You Are Coughing Up Green Mucus

  IntroductionMucus is a moist film, which helps keep your nose from drying out and protect your lungs from foreign substances, such as bacteria, viruses, dust, and other harmful intruders. It keeps you healthy but you may only notice it whenever you are sick. Mucus becomes thicker when you are sick,...

• Breaking: Asthma Drugs may not Actually Cause Birth Defects

  A new study has shown that asthma treatment may not actually increase the risk of birth defects as generally thought. This is reassuring news for many pregnant women who have asthma and need treatment. There was a very mild increase in the risk of rare birth defects in women who took the medication...

• Cystic Fibrosis Breakthrough in Left Ventricular Cardiac Disturbances

  Cystic fibrosis may be one of the most common autosomal recessive lethal diseases, but there remains much that is unknown about it. It has been established that the disease causes chronic pulmonary disease and is also capable of leading to cor pulmonale with right ventricular dysfunction, but it was...

• Preventing Exacerbations of COPD

  According to a statistic, 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD) around the world. More than 3 million people have died because of COPD in 2005, which corresponds to 5 percent of all deaths globally. This puts COPD as one of the major causes of...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...